Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cg-400549. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR4 | P51679 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | TTK | P33981 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cg-400549 SCHEMBL29385717 | 1.00 | CCR4 (0.42) | CCR4MAPK14MCHR1HPGDTTK | |
| SCHEMBL2178305 | 0.88 | CCR4 (0.42) | CCR4MAPK14MCHR1HPGDTTK | |
| SCHEMBL2174897 | 0.86 | MAPK14 (0.35) | MAPK14MCHR1 | |
| SCHEMBL2175979 | 0.86 | MAPK14 (0.37) | MAPK14MCHR1 | |
| SCHEMBL2179781 | 0.86 | MAPK14 (0.37) | MAPK14MCHR1 | |
| SCHEMBL2176777 | 0.85 | MAPK14 (0.36) | MAPK14MCHR1 | |
| SCHEMBL2175126 | 0.84 | MCHR1 (0.37) | MAPK14MCHR1 | |
| SCHEMBL2174207 | 0.84 | MAPK14 (0.35) | MAPK14MCHR1 | |
| SCHEMBL2175714 | 0.84 | MAPK14 (0.38) | MAPK14MCHR1 | |
| SCHEMBL2177317 | 0.84 | DRD2 (0.44) | CCR4MCHR1TTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220031607-A1 | INJECTION COMPOSITION CONTAINING FAB I INHIBITOR, AND PREPARATION METHOD THEREFOR | CRYSTALGENOMICS, INC. (KR) | 2022-02-03 | — | — | US | claimed |
| US-20220016098-A1 | ORALLY ADMINISTERED PHARMACEUTICAL COMPOSITION COMPRISING FAB I INHIBITORS AND METHOD FOR PREPARING SAME | CRYSTALGENOMICS, INC. (KR) | 2022-01-20 | — | — | US | claimed |
| EP-3915538-A1 | INJECTION COMPOSITION CONTAINING FAB I INHIBITOR, AND PREPARATION METHOD THEREFOR | Crystalgenomics, Inc. (KR) | 2021-12-01 | — | — | EP | claimed |
| CN-113613627-A | Injection composition containing Fab I inhibitor and preparation method thereof | 晶体基因技术株式会社 | 2021-11-05 | — | — | CN | claimed |
| EP-3824888-A1 | ORALLY ADMINISTERED PHARMACEUTICAL COMPOSITION COMPRISING FAB I INHIBITORS AND METHOD FOR PREPARING SAME | Crystalgenomics, Inc. (KR) | 2021-05-26 | — | — | EP | claimed |
| CN-112423751-A | Orally administered pharmaceutical compositions comprising Fab I inhibitors and methods of making the same | 晶体基因技术株式会社 | 2021-02-26 | — | — | CN | claimed |
| WO-2020017756-A1 | ORALLY ADMINISTERED PHARMACEUTICAL COMPOSITION COMPRISING FAB I INHIBITORS AND METHOD FOR PREPARING SAME | 크리스탈지노믹스(주) | 2020-01-23 | — | — | WO | claimed |
| EP-1948601-B1 | FAB I INHIBITOR AND PROCESS FOR PREPARING SAME | CRYSTALGENOMICS INC (KR) | 2016-04-13 | — | — | EP | claimed |
| US-7973060-B2 | Fab I inhibitor and process for preparing same | CRYSTALGENOMICS, INC. (KR) | 2011-07-05 | — | — | US | claimed |
| EP-1948601-A1 | FAB I INHIBITOR AND PROCESS FOR PREPARING SAME | Crystalgenomics, Inc. (KR) | 2008-07-30 | — | — | EP | claimed |
| US-20070135465-A1 | Fab I Inhibitor and Process for Preparing Same | CRYSTALGENOMICS, INC. (KR) | 2007-06-14 | — | — | US | claimed |
| WO-2007043835-A1 | FAB I INHIBITOR AND PROCESS FOR PREPARING SAME | CRYSTALGENOMICS, INC. (KR) | 2007-04-19 | — | — | WO | claimed |
| US-20220031607-A1 | INJECTION COMPOSITION CONTAINING FAB I INHIBITOR, AND PREPARATION METHOD THEREFOR | CRYSTALGENOMICS, INC. (KR) | 2022-02-03 | — | — | US | disclosed |
| US-20220031607-A1 | INJECTION COMPOSITION CONTAINING FAB I INHIBITOR, AND PREPARATION METHOD THEREFOR | CRYSTALGENOMICS, INC. (KR) | 2022-02-03 | — | — | US | disclosed |
| US-20220016098-A1 | ORALLY ADMINISTERED PHARMACEUTICAL COMPOSITION COMPRISING FAB I INHIBITORS AND METHOD FOR PREPARING SAME | CRYSTALGENOMICS, INC. (KR) | 2022-01-20 | — | — | US | disclosed |
| US-20220016098-A1 | ORALLY ADMINISTERED PHARMACEUTICAL COMPOSITION COMPRISING FAB I INHIBITORS AND METHOD FOR PREPARING SAME | CRYSTALGENOMICS, INC. (KR) | 2022-01-20 | — | — | US | disclosed |
| US-7973060-B2 | Fab I inhibitor and process for preparing same | CRYSTALGENOMICS, INC. (KR) | 2011-07-05 | — | — | US | disclosed |
| EP-1948601-A1 | FAB I INHIBITOR AND PROCESS FOR PREPARING SAME | Crystalgenomics, Inc. (KR) | 2008-07-30 | — | — | EP | disclosed |
| US-20070135465-A1 | Fab I Inhibitor and Process for Preparing Same | CRYSTALGENOMICS, INC. (KR) | 2007-06-14 | — | — | US | disclosed |
| WO-2007043835-A1 | FAB I INHIBITOR AND PROCESS FOR PREPARING SAME | CRYSTALGENOMICS, INC. (KR) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220016098-A1 | ORALLY ADMINISTERED PHARMACEUTICAL COMPOSITION COMPRISING FAB I INHIBITORS AND METHOD FOR PREPARING SAME | FCGRT, PEF1, SI | CCR4 4187/4885MAPK14 4057/4885MCHR1 4495/4885 |
| US-20070135465-A1 | Fab I Inhibitor and Process for Preparing Same | TFPI, TFPI2, FCGRT | CCR4 4278/4885MAPK14 1791/4885MCHR1 4586/4885 |
| US-20220031607-A1 | INJECTION COMPOSITION CONTAINING FAB I INHIBITOR, AND PREPARATION METHOD THEREFOR | FAR1, NOTUM, IDE | CCR4 3960/4885MAPK14 2055/4885MCHR1 4410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.